Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease

Neurodegenerative Diseases

Volumn 7, Issue 4, 2010, Pages 251-259

  Kaiser, Elmar ^a   Schoenknecht, Peter ^a   Kassner, Stefan ^c   Hildebrandt, Wulf ^b   Kinscherf, Ralf ^d   Schroeder, Johannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Centre for Biomedicine and Medical Technology Mannheim CBTM   (Germany)

Author keywords

Alzheimer's disease; Amino acids; Cerebrospinal fluid; Mild cognitive impairment

Indexed keywords

2 AMINOADIPATE AMINOTRANSFERASE; 2 AMINOBUTYRIC ACID; 3 METHYLHISTIDINE; ALANINE; AMINO ACID; AMMONIA; ARGININE; ASPARTIC ACID; BETA ALANINE; CARNOSINE; CITRULLINE; CYSTATHIONINE; CYSTINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; NORLEUCINE; ORNITHINE; PHENETHYLAMINE; PHENYLALANINE; TAURINE; THREONINE; TRYPTOPHAN; TYROSINE; UREA; VALINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR MECHANICS; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

AGED; ALZHEIMER DISEASE; AMINO ACIDS; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROCHEMISTRY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UP-REGULATION;

EID: 77953797283     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000287953     Document Type: Article

References (46)

1. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006; 368: 387-403.
2. Mattsson N, Zetterberg H, Londos E, Andreasen N, Lanari A, Jonsson M, Herukka SK, van der Flier WM, Evers M, Rich K, Kaiser E, Rosén E, Aarsland D, Jelle-Visser P, Schroeder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Parnetti L, Joenhagen ME, Minthon L, Winblad B, Blennow K: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
3. Thomann PA, Kaiser E, Schoenknecht P, Pantel J, Essig M, Schroeder J: Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci 2009; 34: 136-142.
4. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH: Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007; 61: 120-129. (Pubitemid 46363839)
5. Petzold A, Keir G, Warren J, Fox N, Rossor MN: A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007; 4: 185-194.
6. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, Ha SA, Kim JR, Kim JW: Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. BMC Neurol 2007; 7: 14.
7. Degrell I, Helsing K, Nagy E, Niklasson F: Amino acid concentrations in cerebrospinal fluid in presenile and senile dementia of Alzheimer type and multi-infarct dementia. Arch Gerontol Geriatr 1989; 9: 123-135.
8. Gelot MA, Jeandel C, Belleville F, Nabet P, Penin F, Cuny G: Cerebrospinal fluid amino acids in Alzheimer's disease. Arch Neurol 1993; 24: 1097-1105.
9. Martinez M, Frank A, Tejedor ED, Hernauz A: Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J Neural Transm Park Dis Dement Sect 1993; 6: 1-9.
10. Pomara N, Singh R, Deptula D, Chou JC, Schwartz MB, LeWitt PA: Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry 1992; 149: 251-254.
11. Smith CT, Bowen DM, Francis PT, Snowden JS, Neary D: Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 1985; 48: 469-471.
12. Tohgi H, Abe T, Takahashi S, Kumura M: A selective reduction of excitatory amnio acids in cerebrospinal fluid of patients with Alzheimer type dementia compared with vascular dementia of the Binswanger type. Neurosci Lett 1992; 14: 5-8.
13. D'Aniello A, Fisher G, Migliaccio N, Cammisa G, D'Aniello E, Spinelli P: Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Lett 2005; 388: 49-53.
14. Elison DW, Beal MF, Mazurek MF, Bird ED, Martin JB: A post-mortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol 1986; 20: 616-621.
15. Perry EK, Atack JR, Perry RH, Hardy JA, Dodd PR, Edwardson JA, Blessed G, Tomlinson BE, Fairbairn AF: Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1984; 42: 1402-1410.
16. Sasaki H, Muromoto O, Komzowa I, Arai H, Kosaka K, Iizuka R: Regional distribution of amino acid transmitters in post-mortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 1986; 19: 263-269.
17. Tarbit I, Perry EK, Perry RH, Blessed G, Tomlinson BE: Hippocampal free amino acids in Alzheimer's disease. J Neurochem 1980; 35: 1246-1249.
18. Felipo V, Butterworth RF: Neurobiology of ammonia. Prog Neurobiol 2002; 67: 259-279.
19. Dröge W, Kinscherf R: Aberrant Insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. Antioxid Redox Signal 2008; 10: 661-678.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
21. Levy R: Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994; 6: 63-68.
22. Schoenknecht P, Pantel J, Kruse A, Schroeder J: Prevalence and natural course of aging- associated cognitive decline in a population based sample of 'young-old' subjects. Am J Psychiatry 2005; 11: 2071-2077.
23. Loeb C, Gandolfo C: Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983; 14: 399-401.
24. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
25. Hildebrandt W, Kinscherf R, Hauer K, Holm E, Dröge W: Plasma cystine concentration and redox state in aging and physical exercise. Mech Ageing Dev 2002; 123: 1269-1281.
26. Fisher G, Lorenzo N, Abe H, Fujita E, Frey WH, Emory C, Di Fiore MM, D'Aniello A: Free D - and L -amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids 1998; 15: 263-269.
27. Molina JA, Jimenez-Jimenez FJ, Vargas C, Gomes P, de Bustos F, Orti-Pareja M, Tallon- Barranco A, Benito-LeonJ, Arenas J, Enriquez- de-Salamanca R: Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer disease. J Neural Transm 1998; 105: 279-286.
28. Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR: Changes in the structural complexity of the aged brain. Aging Cell 2007; 6: 275-284.
29. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, Avila J: Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005; 2: 3-18.
30. Kaiser E, Schoenknecht P, Thomann PA, Hunt A, Schroeder J: Influence of delayed CSF storage on concentrations of phosphotau protein (181), total tau protein and betaamyloid (1-42). Neurosci Lett 2007; 417: 193-195.
31. Padmashri R, Sikdar SK: Glutamate transporter blockade affects Ca 2+ responses in astrocytes. Neuroscience 2008; 151: 56-62.
32. Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schroeder J, Kinscherf R: Novel systemic markers for patients with Alzheimer disease? - A pilot study. Curr Alzheimer Res 2008; 5: 358-366.
33. Vesce S, Rossi D, Brambilla L, Volterra A: Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 2007; 82: 57-71.
34. Sethuraman R, Krishnamoorthy MG, Lee TL, Liu EH, Chiang S, Nishimura W, Sakai M, Minami T, Tachibana S: Simultaneous analysis of D - and L -serine in cerebrospinal fluid by use of HPLC. Clin Chem 2007; 53: 1489-1494.
35. Norenberg MD, Rama Rao KV, Jayakumar AR: Signaling factors in the mechanism of ammonia neurotoxicity. Metab Brain Dis 2009; 24: 103-117.
36. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E: Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem 2009; 121: 2015-2020.
37. Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF: Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache 2007; 47: 842-847.
38. Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic amino acids. Lancet 1997; 349: 79-83.
39. Aguilar-Hernandez M, Mendez JD: In vitro glycation of brain aminophospholipids by acetoacetate and its inhibition by urea. Biomed Pharmacother 2007; 61: 693-697.
40. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578.
41. Louin G, Neveux N, Cynober L, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M: Plasma concentrations of arginine and related amino acids following traumatic brain injury: proline as a promising biomarker of brain damage severity. Nitric Oxide 2007; 17: 91-97.
42. Brosnan JT, Brosnan ME: Creatine: endogenous metabolite, dietry and therapeutic supplement. Annu Rev Nutr 2007; 27: 241-261.
43. Buerklen TS, Schlattner U, Homayouni R: The creatine kinase/creatine connection to Alzheimer's disease: CK inactivation, APPCK complexes, and focal creatine deposits. J Biomed Biotechnol 2006; 2006: 35-36.
44. Schoenknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hampel H, Schroeder J: Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 2003; 339: 172-174.
45. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P: Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62: 1580-1584.
46. Griebe M, Daffertshofer M, Stroick M, Syren M, Ahmad-Nejad P, Neumaier M, Backhaus J, Hennerici MG, Fatar M: Infrared spectroscopy: a new diagnostic tool in Alzheimer disease. Neurosci Lett 2007; 420: 29-33.